Anavex Life Sciences Corp. (FRA:12X1)

Market Cap	324.08M -55.5%
Revenue (ttm)	n/a
Net Income	-34.02M
EPS	-0.39
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	234
Open	3.390
Previous Close	3.260
Day's Range	3.390 - 3.390
52-Week Range	2.261 - 11.505
Beta	n/a
RSI	45.11
Earnings Date	Feb 9, 2026

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2004
• Employees: 34
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 12X1

Financial Performance

Financial numbers in USD